Clinical Trials Browser

Myelodysplastic Syndromes, Myeloproliferative Disorders, Neutropenia, Leukemia, Myeloid, Acute

NCT07153497 2026-04-13

Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)

Phase 2 Not yet recruiting

132 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT07354074 2026-03-23

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

Phase 2 Not yet recruiting

50 enrolled

MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07468916 2026-03-13

Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia

Phase 2 Not yet recruiting

35 enrolled

MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Thrombocytosis, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT07449286 2026-03-04

IFN-α in Relapse Prevention.

Phase 2 Not yet recruiting

100 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT07394153 2026-02-06

PACRIMYEL

Phase 2 Not yet recruiting

30 enrolled

Myeloid

Primary Myelofibrosis

NCT07269470 2025-12-16

Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Phase 2 Not yet recruiting

40 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07007052 2025-11-26

TAGVEN

Phase 2 Not yet recruiting

33 enrolled

Myeloid

Pathologic Complete Response, Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT06987058 2025-09-24

ROVER-01

Phase 2 Not yet recruiting

10 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasm Metastasis, Recurrence, Leukemia, Myeloid, Acute

NCT06900088 2025-03-28

Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients

Phase 2 Not yet recruiting

20 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06598969 2024-09-19

TMLI-MA

Phase 2 Not yet recruiting

58 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06602323 2024-09-19

TMLI-RI

Phase 2 Not yet recruiting

34 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06050941 2024-03-05

Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS

Phase 2 Not yet recruiting

60 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04451200 2020-11-17

BUSEQ

Phase 2 Not yet recruiting

82 enrolled

Myeloid

Myeloproliferative Disorders

Clinical Trials

MYELO-CAN:ABX

Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia

IFN-α in Relapse Prevention.

PACRIMYEL

Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

TAGVEN

ROVER-01

Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients

TMLI-MA

TMLI-RI

Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS

BUSEQ